NATIONAL LEIOMYOSARCOMA FOUNDATION

                            2026-2027 RESEARCH GRANT ANNOUNCEMENT

LOI deadline: April 15^th, 2025

Please submit to Matthew Hemming, M.D., PhD.: matthew.hemming@umassmemorial.org  and 
Alessandra Maleddu M.D.:  alessandra.maleddu@cuanschutz.edu

Introduction: The National Leiomyosarcoma Foundation (NLMSF) is dedicated to meeting the needs of leiomyosarcoma (LMS) patients, caregivers and families through education and research. In order to facilitate advances in the treatment of LMS through research, the NLMSF is accepting research proposals for pilot studies that will launch “out of the box” ideas and new research trajectories to move the field forward.

Scope of the award/ areas of interest: All direct funds must be used to support LMS research. Proposals involving any scientific discipline are allowed including those related to biomarkers and imaging. This award was created to support basic and translational research. Other highly translational projects that are not based in a traditional wet lab may be considered (for example: in silico computational biology, radiomics, etc.); however, investigators who are considering submitting a non-traditional research project are highly encouraged to discuss the appropriateness of their project ahead of time. Clinical research (interventional trials) will not be supported by this award; however, work studying human samples and annotated data sets obtained from clinical trials is allowed. Studies requiring human samples must show documentation of IRB approval prior to awarding of funds (or document waivers if applicable).

Letter of Intent (LOI) Overview: The NLMSF seeks LOIs for research grant funding. The total award will be $50,000 per year for 2 years.  Indirect costs should not exceed 10% of the total budget.
The LOI should consist of:
1) Proposed research (2 page maximum)
2) Applicant NIH Biosketch

 Key Dates:
LOI due: April 15^th, 2025
Invitations for full proposal sent: May 30^th, 2025
Full proposal due: August 31^st, 2025
Announcement: November 2025
Funding start date: January 2026

_____________________________________________________________________________________________________________________

2025

Clinical outcomes following stereotactic radiosurgery for brain metastases from sarcoma primaries: An international multicenter analysis (Cancer . 2025 Jul 1;131(13):e35931.  doi: 10.1002/cncr.35931.)

Leiomyosarcoma Therapeutic Approaches and Future Directions (7 April 2025) available on-line in the Hematology/Onc0logy Clinics of North America (22 May 2025)
https://www.sciencedirect.com/science/article/abs/pii/S0889858825000450?via%3Dihub

Emerging Role of Blood-based Biomarkers in Sarcomas (2 April 2025) available on-line in the Hematology/Onc0logy Clinics of North America (22 May 2025)
https://www.sciencedirect.com/science/article/abs/pii/S0889858825000401?via%3Dihub

Myxoid Leiomyosarcoma of the Uterus – A Case Report (2 Apr 2025) in Oncology Letters

2024

Dr. Patricia Pautier- a research update in the New England Journal of Medicine

Published November 27, 2024
N Engl J Med 2024;391:2057-2058 
DOI: 10.1056/NEJMc2412479

VOL. 391 NO. 21

Doxorubicin–Trabectedin in Leiomyosarcoma | New England Journal of Medicine

The results of the LMS04 trial reported by Pautier et al. (Sept. 5 issue)¹ are unprecedented in terms of the median progression-free and overall survival. The French Sarcoma Group should be lauded for conducting this large trial in patients with a specific sarcoma subset. However, we would like to raise a few issues. Trabectedin was administered over a period of 3 hours instead of 24 hours, which is standard practice. Robust data indicate that 24-hour administration yields superior tumor control and progression-free survival.² Unlike other drugs, trabectedin does not have cumulative toxic effects. 

CLINICAL TRIALS:

Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma.  Clinical trial information: NCT06088290.

Authors: Gregory Michael Cote, Sant P. Chawla, George Demetri, Bernd Kasper, Robin Lewis Jones, Javier Martin Broto, Joseph Wooley, Mia C. Weiss, Salvatore Tafuto, Giuseppe Badalamenti, Irene Carrasco-Garcia, Paloma Peinado, Jean-Yves Blay, Gaston Boggio, Cristian Marcelo Fernandez, Antonio Nieto, Carmen Maria Kahatt, Ali Hassan Zeaiter, and Axel Le Cesne  Click this title for research update:

Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma. | Journal of Clinical Oncology

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

July 25, 2024 updated by: Polaris Group

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

Study Overview

This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

A Phase 3 Study of ADI-PEG 20 or Placebo Plus Gemcitabine and …

www.mskcc.org/cancer-care/clinical-trials/24-147

Full Title ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial (WIRB) Purpose Leiomyosarcoma is a type of cancer that forms in smooth muscle. Researchers want to see if adding ADI-PEG 20 to the usual chemotherapy for leiomyosarcoma works better than chemotherapy alone 

Investigator                        Co investigator

Viswatej (Vishu) Avutu        Robert Maki

Emerging Trends in Immunotherapy for Adult Sarcomas
Marium Husain, Luxi Chen, David Liebner, Joal Beane, Mark Rubinstein, Raphael Pollock, Claire Verschraegen, Gabriel Tinoco

2022

Molecular subtypes of leiomyosarcoma: Moving toward a consensus (2 Nov 2022)
https://onlinelibrary.wiley.com/doi/full/10.1002/ctd2.149

Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma 
(2 Nov 2022)  https://link.springer.com/article/10.1245/s10434-022-12517-w

CLINICAL TRIALS: TARGETED THERAPY (2 Aug 2022)
Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
https://aacrjournals.org/clincancerres/article-abstract/28/15/3225/707113/Phase-II-Clinical-Trial-of-Eribulin-Gemcitabine?redirectedFrom=fulltext

Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma (2 Aug 2022)

A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates. (2 Aug 2023)

 Retroperitoneal LMS Nomogram Model (3 Jul 2022)

Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA Kasper B, Wilky BA. Researchers of the NLMSF-SPAEN International LMS Research Roundtable – Executive Committee and Workgroup Leadership (13 Jun 2022)

PRESS RELEASE NEWS  from Dr. Brian Van Tine about UNESBULIN: for LMS:  (3 Jun 2022)
https://ir.ptcbio.com/…/preliminary-results-presented…Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

Surgical management strategy for leiomyosarcoma of Zone I-II inferior vena cava: A case series  (3 Jun 2022)   https://pubmed.ncbi.nlm.nih.gov/35665732/

Article by Dr. Matthew Hemming in the Journal of TRANSLATIONAL CANCER MECHANISMS AND THERAPY| 
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression (1 Jun 2022)
https://aacrjournals.org/clincancerres/article-abstract/28/11/2397/698931/Preclinical-Modeling-of-Leiomyosarcoma-Identifies?redirectedFrom=fulltextz
Note:  This research publication update relates to a research project being funded by the NLMSF being done by Dr. Matt Hemming 

Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions (13 Apr 2022)
Brief Summary of the research update: https://pubmed.ncbi.nlm.nih.gov/35454875/
The complete publication (1 Apr 2022): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029111/

Here is the conclusion:
Conclusion of the study: The review of current literature led to the conclusion that we still have no reliable method to distinguish leiomyomas and leiomyosarcomas preoperatively. The studies in this field have, in most cases, retrospective design and the number of cases seems to be insufficient to achieve conclusive results. The rarity of malignant myometrial lesions is an obvious reason that explains such a situation.
However, on the horizon, we can identify new game-changing options that have the potential to revolutionize our practice in cases of myometrial lesions.
On one hand, there are many ambitious researchers introducing novel multi-parametric diagnostic scales, having promising performances in differentiating such lesions.
On the other hand, the recent advancement of machine learning and artificial intelligence constitute promising novel tools that give hope that we can solve this problem completely. Nowadays, the biggest challenge for researchers and clinicians is organizing multicenter databases that include numerous cases of both LM and LMS, and using them for the development and validation of these novel tools.

What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? (11 Mar 2022)

Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas
Current Treatment Options in Oncology (2022)Cite this article (16 Feb 2022)

Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review (Dec 2021)

Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas ( 1 Aug 2021)

2021:

Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma.(ASCO Abstract 2021)

Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma. (ASCO Abstract 2021)

• Prognostic relevance of the hexosamine biosynthesis pathway . 
  In order to identify metabolic pathways activated in leiomyosarcoma (LMS), we analyzed transcriptomic profiles of distinct subtypes of LMS in several datasets. Primary, recurrent and metastatic tumors in the subtype 2 of LMS showed consistent enrichment of genes involved in hexosamine biosynthesis pathway (HBP).   https://pubmed.ncbi.nlm.nih.gov/33941787/   and    https://www.nature.com/articles/s41525-021-00193-w
• Dr. Matt Hemming’s Presentation
• 2019  Research article publication
• Dr. Brian Crompton and Dr Jonathan Trent’s Presentations
• Dr, Trent’s  presentation – references Dr. Junaid Arshad’s 2020 research publication
• Treatment and outcomes of soft tissue sarcoma of groin, hip and thigh: a retrospective review from a tertiary care hospital
• Technical considerations for radical resection of a primary leiomyosarcoma of the vena cava
• Is compartmental surgery always mandatory in retroperitoneal liposarcoma? A case report of multifocal synchronous well-differentiated liposarcoma
• CLINICAL TRIAL ALERT:   See video by Dr. Abdul Razak regarding a Phase 2 trial evaluating Olarapib combined with other new drugs through this clinical trial:  NCT03851614: This is an active basket trial study including LMS but not recruiting at this time;  information to be aware of in this OncLive video presentation.
• Dr. Mattew Ingham –  Recorded presentation on  recent Uterine LMS research – Video
• Dr. Matthew Ingham –    FDA Grants Orphan Drug Status to Sotigalimab for Patients With Soft Tissue Sarcoma
• EPIGENETIC SIGNATURE AND DIFFERENTIATED LEIOJYOSARCOMA SUBTYPES includes ONCOTARGET VIDEO
• PubMed 2018 article: Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma
• FRONTIERS –  CELL AND DEVELOPMENTAL BIOLOGY Article – June, 2021 Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma
• Integrative genomic and transcriptomic analysis of leiomyosarcoma
• TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
• Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
• KIF15 upregulation promotes leiomyosarcoma cell growth via promoting USP15-mediated DEK deubiquitylation
• CARIS PRECISION ONCOLOGY LIFE SCIENCE: Leiomyosarcoma (LMS) is a rare group of mesenchymal malignancies found in the uterus, retroperitoneum, skin, or other soft-tissue sites. Treatment for LMS is extrapolated from trials including both uterine (uLMS) and non-uLMS subtypes, although whether they respond similarly and have similar outcomes from treatment is not clear. We examined the molecular composition of LMS by site of origin to better inform future drug development and trial design.
• Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
• Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments
• Primary Pulmonary Artery Sarcoma Confined to the Left Pulmonary Artery
• Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent
• Leiomyosarcoma of the urinary bladder: A SEER database study and comparison to leiomyosarcomas of the uterus and extremities/trunk
• Inflammatory leiomyosarcoma of the head and neck case report
• A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
• Containing Cumulative Postoperative Morbidity in Patients with Retroperitoneal Sarcoma May Improve Long-Term Prognosis
• Adult genitourinary sarcoma: The era of optional chemotherapeutic agents for soft tissue sarcoma
• NKX6-1 mediates cancer stem-like properties and regulates sonic hedgehog signaling in l leiomyosarcoma
• What is Hedgehog signaling: The hedgehog signaling pathway is one of many complex cell signaling mechanisms found within multicellular organisms, and has a very important role within developmental tumor biology / tumorigenesis (production of a new growth or growths)    It is already known that Sonic hedgehog (Shh) pathway is important for the evolution of radio and chemo-resistance of several types of tumors.
• Next-generation sequencing for the management of sarcomas with no known driver mutations
• Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma.
• A preliminary study of deep learning-based treatment response prediction for soft tissue sarcoma using longitudinal diffusion MRI
• Leiomyosarcoma – continuing education research information as of Jan 2021
• A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
• Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry
• PubMed article: Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas: https://pubmed.ncbi.nlm.nih.gov/33788262/
• Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multi-center Study of the Italian Sarcoma Group:  https://pubmed.ncbi.nlm.nih.gov/33801399/
• NBTXR3 Activity in Soft Tissue Sarcoma Could Be Replicated in Other Cancers
• Next-Generation sequencing reveals potentially actionable mutations in sarcoma
• The role of ¹⁸ F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study 
• Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma   (Cancer Res Clin Onc – 2020 Sep 20)  

2020:

• Current explorations of nutrition and the gut microbiome: a …

  pubmed.ncbi.nlm.nih.gov/32211860

  The microbiota utilize and produce micronutrients; the bidirectional relationship between micronutrition and the gut microbiome is emerging. Conclusions: Nutrition has profound effects on microbial composition, in turn affecting wide-ranging metabolic, hormonal, and neurological processes.
• Sarcoma Experts Elucidate on Combination Chemotherapy Regimens – Sarah Cannon Cancer Institute

• Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups

• A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy
• Georgios_Kantidakis_Presentation_ESMO2020
• Guide Patient election for Resection of Sarcoma Lung metastases
• Radiotherapy for Adult Soft Tissue Sarcomas of the Head and Neck
• Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
• PharmaMar presents results of trabectedin & doxorubicin for first line treatment of leiomyosarcomas at ASCO 2020
• Madrid, June 1^st, 2020.- PharmaMar (MSE:PHM) has announced that the final results from the Phase II study of trabectedin in combination with doxorubicin for the treatment of patients with advanced metastatic uterine and soft tissue leiomyosarcoma have been presented in an Oral Abstract Session at the  American Society of Clinical Oncology (ASCO) Annual Meeting, that was held on May 29^th to 31^st, 2020.

  Under the title “A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study” (Abstract 11506), Patricia Pautier, MD, from the Medical Oncology Department, Institut Gustave Roussy, Villejuif, France, has concluded that trabectedin in combination with doxorubicin is an effective first-line treatment for patients with leiomyosarcoma.

  The study achieved its primary and secondary endpoints, with a median Progression-Free Survival (PFS) of 10.1 months; a median Overall Survival (OS) of 34.4 months and an acceptable safety profile.

  As a reference (not comparable head-to-head studies), the most recent results of other doxorubicin combinations, such as those presented in ASCO 2019 in the “ANNOUNCE” Phase III study (doxorubicin + olaratumumab), reported a median PFS of 6.9 months, and an OS of 21.9 months (ASCO 2019 LBA3)[1].

  Patricia Pautier, MD, said: “Combination of doxorubicin and trabectedin constitutes an active first-line therapy for patients with uterine and soft tissue leiomyosarcoma. Results in overall response rate, progression free survival and now in overall survival are very encouraging.” And added: “Results of the LMS04 trial, a randomized phase-III study comparing this combination followed by trabectedin versus doxorubicin alone in 1st-line therapy in metastatic LMS are pending.”

2019: 

Epub 2019 Jun 4.

Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma

Ali Amin-Mansour ¹, Suzanne George ², Stefano Sioletic ³, Scott L Carter ¹, Mara Rosenberg ¹, Amaro Taylor-Weiner ¹, Chip Stewart ¹, Aaron Chevalier ¹, Sara Seepo ¹, Adam Tracy ¹, Gad Getz ¹, Jason L Hornick ³, Marisa R Nucci ³, Bradley Quade ³, George D Demetri ^2 4, Chandrajit P Raut ⁵, Levi A Garraway ^1 2 6, Eliezer M Van Allen ^7 2 6, Andrew J Wagner ⁸

Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma – PubMed (nih.gov)

Full Journal article:   Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma | Clinical Cancer Research | American Association for Cancer Research (aacrjournals.org)

• BRCA ½ Functional Loss Defines a Targetable Subset in Leiomyosarcoma
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656468/
• 
• Dr. Breelyn Wilky at Univ. of Colorado Health Sciences, Denver, CO recently gave a talk on some of the research that being developed in the lab and in clinic on improving outcomes with immunotherapy in sarcomas. It’s long and pretty scientific-focused, but reviews the major immunotherapy trials for sarcomas, and talks about ideas about how to move forward. View the video here.
• CT imaging improves histopathological grading of retroperitoneal leiomyosarcomas
• Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study 
• of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
• Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
• Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition

  Researchers find evidence a cancer drug may be extended to many more patients

  Leiomyosarcoma: A rare soft tissue cancer arising from multiple organs

  Leiomyosarcoma of the Prostate: Case Report and Review of 54 Previously Published Cases

2018:

Soft Tissue and Uterine Leiomyosarcoma
Suzanne George,  César Serrano, Martee L. Hensley, and Isabelle Ray-Coquard (10 Jan 2018)

• Cutaneous leiomyosarcoma on the trunk: An unusual presentation with an aggressive course – Case report and review of literature
• Treating LMS separately from other soft tissue sarcomas
• Hypoxia-inducible factor 1α predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall
   
• Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: A systematic review with meta-analysis

  BMC Cancer   ||Full Text
• Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
• Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model
• Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease
• A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma
• ELSEVIER RESEARCH ARTICLES – UPDATES ON LEIOMYOSARCOMA

  https://www.sciencedirect.com/search?qs=leiomyosarcoma&show=25&sortBy=relevance –  

  You can go to this site directly for information updates on Leiomyosarcoma  – There are many articles to see for LMS and ULMS.
   
• UPDATE FROM THE NATIONAL INSTITUTES OF HEALTH (NIH):
  Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for Soft Tissue Sarcomas

  https://www.ncbi.nlm.nih.gov/pubmed/30785874
• Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma
• Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity
• 

• Dr. Lara Davis, OHSU physician, researcher  shares her research: Discovery and characterization of novel, recurrent, targetable ALK fusions in leiomyosarcoma

  The result of this research provides the first validation of a targetable oncogenic kinase fusion as a driver in a subset of leiomyosarcomas. Overall, these findings suggest that some soft tissue sarcomas may harbor previously unknown kinase gene translocations, and their discovery may propel new therapeutic strategies in this treatment-refractory cancer.

  Read this published research article. 

• Discovery and characterization of recurrent, targetable ALK fusions in leiomyosarcoma
• Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma  – see the results discussed regarding Leiomyosarcoma
• Trabectedin, Doxorubicin, and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
   
• Cancer research stories from Stanford Medicine and the Stanford Cancer Institute
  Read about cancer research from Stanford Medicine’s News & Publications
  Twitter updates available @StanfordCancer
  • In select sarcoma subtypes, researchers determined the disease control rate (DCR) with sorafenib plus dacarbazine. They examined patients with leiomyosarcoma (LMS), synovial sarcoma (SS), or malignant peripheral nerve sheath tumors (MPNST) with up to two previous lines of therapy and adequate hepatic, renal, and marrow function. Treatment regimen for these subjects comprised 3-week cycles of sorafenib at 400 mg oral twice daily and dacarbazine 1,000 mg/m2 intravenously (later reduced to 850 mg/m2). An 18-week DCR of 46% was documented in this study. Modest clinical activity of dacarbazine + sorafenib was evident in patients with these diagnoses. Dacarbazine + sorafenib was feasible and related to favorable disease-control rates; however, this combination also increased the potential for significant toxicity. Read the full article on The Oncologist

• Larotrectinib Shows Promise for Patients With NTRK-fusion …

• NTRK fusion is associated with several cancers, including infantile fibrosarcoma, which can require amputation or morbid surgery when disease is locally advanced. For this phase 1/2 trial (ClinicalTrials.gov Identifier: NCT02637687), researchers enrolled 11 patients with infantile fibrosarcoma (7 patients) or another sarcoma subtype (4 patients) to receive larotrectinib followed by surgery.
   
  “This is very exciting, but only applies to 0.1% of sarcomas.  But, it is worth looking into more.  I have seen one sarcoma with
  one NTRK fusion and it was very exciting.” – from Dr. Neeta Somaiah, MD, Sarcoma Research, Anderson Cancer Center.
• A phase II study of tumor ablation in patients with metastatic sarcoma stable on chemotherapy
• A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US
• A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC).
• A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers
• Cancer ‘vaccine’ eliminates tumors in mice
• DEFEATING CANCER / PRECISION MEDICINE / PERSONALIZED CARE
• Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: The EORTC 62961-ESHO 95 randomized clinical trial
• Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma

• External beam radiation therapy for resectable soft tissue sarcoma: A systematic review and meta-analysis

  Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas

  Identification of potential prognostic small nucleolar RNA biomarkers for predicting overall survival in patients with sarcoma

  Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas

  Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma

   
• Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
• Molecular studies of human carcinomas and sarcomas
• Multidisciplinary Oncovascular Surgery is Safe and Effective in the Treatment of Intra-abdominal and Retroperitoneal Sarcomas: A Retrospective Single Centre Cohort Study and a Comprehensive Literature Review
• Next-generation sequencing for patients with sarcoma: A single center experience

  Nivolumab With Ipilimumab Promising for Pretreated Metastatic Sarcoma

  Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)

  Options for Adjuvant Therapy for Uterine Leiomyosarcoma

  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

  Renal Function Preservation in Surgical Resection of Primary Inferior Vena Cava Leiomyosarcoma Involving the Renal Veins:

  Sarcoma management is slowly evolving 

  Salvage therapy in advanced adult soft tissue sarcoma: A systematic review and meta-analysis of randomized trials

• Soft Tissue and Uterine Leiomyosarcoma

• Systemic treatment in adult uterine sarcomas

  T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

• The activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine

  Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis

  Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial

• Leiomyosarcoma Articles by Dr. Alexander Lazar:

  Dr. Alexander Lazar (medical advisory council member) is a research pathologist from MD Anderson Cancer Center in Houston, Texas.

  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas

  Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma

  Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas

  Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value